Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Assets (2016 - 2025)

Historic Return on Assets for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to 0.35%.

  • Lineage Cell Therapeutics' Return on Assets fell 1500.0% to 0.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.35%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 0.17% for FY2024, which is 200.0% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Return on Assets stood at 0.35% for Q3 2025, which was down 1500.0% from 0.31% recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Return on Assets peaked at 0.1% during Q3 2021, and registered a low of 0.36% during Q3 2022.
  • In the last 5 years, Lineage Cell Therapeutics' Return on Assets had a median value of 0.21% in 2023 and averaged 0.23%.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Return on Assets soared by 2900bps in 2021 and then crashed by -2600bps in 2022.
  • Lineage Cell Therapeutics' Return on Assets (Quarter) stood at 0.28% in 2021, then grew by 25bps to 0.21% in 2022, then decreased by 0bps to 0.21% in 2023, then rose by 15bps to 0.18% in 2024, then plummeted by -100bps to 0.35% in 2025.
  • Its Return on Assets was 0.35% in Q3 2025, compared to 0.31% in Q2 2025 and 0.16% in Q1 2025.